ClinicalTrials.gg
CompletedNCT01400828Updated Jul 10, 2014

Investigate the Safety/Tolerability and Efficacy of Bilastine 20mg in Korean Patients With Seasonal Allergic Rhinitis

A Phase 3 interventional study of Bilastine and Desloratadine in Seasonal Allergic Rhinitis, sponsored by Yuhan Corporation. Completed at 1 site in Korea, Republic of. Open to participants aged 12 Years to 70 Years. Per ClinicalTrials.gov, last updated 2014-07-10.

Sponsored by Yuhan Corporation · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
239
Allocation
Randomized
Ages
12 Years to 70 Years
Sex
All
01

Study summary

The objective of the study was to determine the efficacy and tolerability of 20 mg of Bilastine, compared to Desloratadine and placebo for the treatment of Seasonal Allergic Rhinitis.

02

Conditions studied

  • Seasonal Allergic Rhinitis
03

In context

Rhinitis, Allergic, Seasonal

404 studies on the registry are indexed under Rhinitis, Allergic, Seasonal; 24 are open to participants now.

This study's enrollment of 239 is above the median of 131 across 366 interventional studies indexed under Rhinitis, Allergic, Seasonal.

Browse Rhinitis, Allergic, Seasonal studies →

Lead sponsor

Yuhan Corporation is the lead sponsor of 110 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The study disease was diagnosed on the basis of clinical criteria: Nasal symptoms (presence of nasal blockage, sneezing, nasal itching and rhinorrhea) and non-nasal symptoms (ocular itching, lacrimation, itching of ears and/or palate and ocular redness), as well as the skin prick test performed at the time of selection or within the year prior to entering.
  • Patients with history of Seasonal Allergic Rhinitis, positive skin prick test and symptoms were included if they were between 12 and 70 years old, gave their , attended the required visits scheduled and also underwent a complete medical examination..

Exclusion criteria

Exclusion Criteria:

  • Patients were excluded if they had a significant nasal abnormality which could interfere with the aim of the study, acute or chronic sinusitis, asthma or any condition, disease or that could be harmed.
  • Patients were not allowed to take forbidden medications or not comply the study requirements.
  • Patients who were currently participating in or had participated in another clinical trial within the previous three months or were planning to travel outside of the study area during the course of the study were excluded.
  • Pregnant or breast-feeding women were also excluded.
  • Women of had a pregnancy test done
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
239 participants (actual)

Study arms

  • Experimental
    Bilastine

    Intervention: Drug: Bilastine

    Drug: Bilastine

  • Active comparator
    Desloratadine

    Intervention: Drug: Desloratadine

    Drug: Desloratadine

  • Placebo comparator
    Placebo

    Intervention: Drug: Placebo

    Drug: Placebo

Interventions

  • 20 mg (encapsulated) tablets QD/14 days

  • 5 mg (encapsulated) tablets QD/14 days

    Also known as: Aerius

  • DrugPlacebo

    (encapsulated) Tablets QD/14 days

06

What researchers measure

Primary outcomes

  1. AUC of TSS

    The area under curve (AUC) of the total symptom score (TSS) since basal visit to D14 visit according to the patient's assessment

    Time frame: 14 days

Secondary outcomes

  1. Change in TSS. Reflective symptoms

    Change in the reflective total score on symptom scale on D14 visit and day7 visit versus D0 visit (baseline) according to the patient´s assessment on the previous 12 hours.

    Time frame: 14 days

  2. Change in TSS. Instantaneous score

    Change in the total score on symptom scale on D7 and D14 visits versus D0 visit (baseline) according to the patient's assessment (instantaneous score).

    Time frame: 14days

  3. Change in total nasal symptom score (TNSS)

    Change in nasal symptom score on symptom scale on D7 and D14 visits versus D0 visit (baseline) according to the patient's and investigator's assessment

    Time frame: 14 days

  4. •Change in total non-nasal symptom score (TNNSS)

    Change in non-nasal symptom score on symptom scale on D7 and D14 visits versus D0 visit (baseline) according to the patient's and investigator's assessment

    Time frame: 14 days

  5. VAS of discomfort

    Overall assessment of discomfort caused by allergic rhinitis using a visual analog scale (VAS) on D7 and D14 versus D0.

    Time frame: 14 days

  6. CGI

    Investigator's overall clinical impression (CGI)

    Time frame: 14 days

  7. •Allergic rhinitis (AR) quality of life (QoL) questionnaire (RQLQ)

    Quality of Life change versus baseline.

    Time frame: 14 days

  8. responde's rate

    Patients were analysed based on their total symptoms score decrease from baseline (\<25%, 25%-50%, 50%-75%, \>75%).

    Time frame: 14 days

  9. safety assessment

    comparison of the adverse event profiles throughout the course of the study, ECGs and safety blood tests on D0 and D14.

    Time frame: 14 days

07

Study locations

1 site
  • Yonsei University college of Medicine, Gangnam Severance Hospital
    Seoul, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2011, a primary completion of Jun 2013 and a completion of May 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2011
First posted
Jul 22, 2011
Start
Jun 2011
Primary completionActual
Jun 2013
CompletionActual
May 2014
Last update
Jul 10, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01400828
Lead sponsor
Yuhan Corporation
Responsible party
Sponsor
First posted
Jul 22, 2011
Start date
Jun 2011
Primary completion
Jun 2013
Completion
May 2014
Last update
Jul 10, 2014

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bilastine

Start the discussion